Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s share price reached a new 52-week high on Monday . The company traded as high as $48.87 and last traded at $47.99, with a volume of 321456 shares traded. The stock had previously closed at $47.75.
Gemini Therapeutics Stock Performance
The company has a market cap of $2.08 billion, a PE ratio of -47.99 and a beta of -0.12. The stock has a 50 day moving average of $48.12 and a 200-day moving average of $41.16.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
See Also
- Five stocks we like better than Gemini Therapeutics
- What is a Special Dividend?
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- ETF Screener: Uses and Step-by-Step Guide
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- Stock Splits, Do They Really Impact Investors?
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.